Anti-Diabetes Drugs - Niger | Statista Market Forecast

In Niger, the revenue in the Anti-Diabetes Drugs market is forecasted to reach US$10.74m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 8.52%, leading to a market volume of US$16.17m by 2029.
When compared globally, United States will generate the highest revenue, amounting to US$37.84bn in 2024.
The demand for anti-diabetes drugs in Niger has been steadily increasing due to the rising prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Niger is a growing market due to the increasing prevalence of diabetes in the country.

Customer preferences: Niger has a high prevalence of diabetes, with an estimated 5.2% of the population living with the disease. As a result, there is a growing demand for anti-diabetes drugs in the country. However, due to the high poverty levels in Niger, many people cannot afford the high cost of these drugs. This has led to a preference for cheaper, generic versions of the drugs.

Trends in the market: The anti-diabetes drugs market in Niger is primarily driven by the increasing prevalence of diabetes in the country. This has led to a growing demand for drugs such as metformin, sulfonylureas, and insulin. However, due to the high poverty levels in Niger, the market for these drugs is largely dominated by cheaper, generic versions. Additionally, there is a growing trend towards the use of traditional medicine in the treatment of diabetes in Niger.

Local special circumstances: One of the major challenges in the anti-diabetes drugs market in Niger is the lack of access to healthcare. Many people in the country live in rural areas with limited access to healthcare facilities. This has led to a lack of awareness about diabetes and its treatment options. Additionally, there is a lack of trained healthcare professionals in the country, which has further limited access to diabetes treatment.

Underlying macroeconomic factors: Niger is one of the poorest countries in the world, with high levels of poverty and unemployment. This has led to a lack of access to healthcare and a preference for cheaper, generic versions of drugs. Additionally, the country has a high burden of disease, with a high prevalence of infectious diseases such as malaria and tuberculosis. This has led to a limited focus on non-communicable diseases such as diabetes. However, with the increasing prevalence of diabetes in the country, there is a growing need for investment in the anti-diabetes drugs market in Niger.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.